FAQ: Nutriband's AVERSA Fentanyl Abuse-Deterrent Patch and Market Potential

What is Nutriband Inc. and what is their main focus?

Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company primarily engaged in developing transdermal pharmaceutical products. Their main focus is on abuse-deterrent drug delivery technologies, with AVERSA Fentanyl as their lead product.

What is AVERSA Fentanyl and how does it work?

AVERSA Fentanyl is an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the risk of opioid misuse. The AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Why is this development significant for the pharmaceutical industry?

This development addresses the critical issue of opioid abuse by providing an abuse-deterrent solution. Market projections estimate annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the category, representing substantial market potential.

What are the key milestones and timeline for AVERSA Fentanyl?

Following completion of manufacturing scale-up with Kindeva Drug Delivery, Nutriband expects to begin a human abuse liability study in early 2026 and file a New Drug Application later that year. The company was featured in an October 23, 2025, Channelchek report summarizing their progress.

How is Nutriband funding its research and development?

According to Noble Capital Markets, Nutriband has the ability to fund R&D through its contract manufacturing division without shareholder dilution. Noble reaffirmed its Outperform rating and $15 price target based on this financial strategy.

Where can investors find more information about Nutriband?

Investors can view the full Channelchek report at https://ibn.fm/bClpc and access the latest news and updates relating to NTRB in the company’s newsroom at https://ibn.fm/NTRB. The company’s website is www.nutriband.com.

Who is involved in the development and manufacturing of AVERSA Fentanyl?

Nutriband is developing the technology and has partnered with Kindeva Drug Delivery for manufacturing scale-up. The progress was highlighted in a Channelchek report by Noble Capital Markets, which follows the company’s developments.

What is the market potential for AVERSA Fentanyl?

Market projections estimate annual sales of $200 million for AVERSA Fentanyl, with potential to reach $800 million annually if the FDA mandates abuse-deterrent patches across the entire opioid patch category. This represents significant commercial opportunity for the company.